



Colloque 16 Septembre 2021

Approches Innovantes dans la lutte contre l'antibiorésistance



Prof. Djamel Drider
Université de Lille



Dr. Philippe Gabant
Co-founder & CSO
Syngulon SA, Seraing (Belgique)


Les peptides antimicrobiens : pourquoi et comment ?

Les bactériocines


Plan de la présentation

- Eléments généraux sur les bactériocines (D3-D10).
- Partie D. Drider, Université de Lille (D11-D19).
- Partie P. Gabant, Syngulon SA, Seraing, Belgique. D20-D34

Bacteriocins



Prof. André GRATIA (1893-1950)
Prof at ULB and later at ULiège





1925 (colicin)

Bacteriocins are Antimicrobial Peptides (AMPs) :

- ribosomally synthesized by **Gram-positive**, **Gram-negative** and Archaea
- scheme of production of primary metabolites
- proteinaceous nature
- non-cytotoxic (usually)
- active against bacteria which are phylogenetically close to the producing strains **but...**
- stable at different pHs and temperatures
- no universal classification common scheme



Data and database (s)



APD3. <http://aps.unmc.edu/AP> (2016)
OCINS. <http://ocins.cftri.com/ocins/> (2019)
BACTIBASE. bactibase.hammamilab.org/main.php (2010 updated)

Mode of action of colicin-like bacteriocins






Image: LISM - CNRS (cnrs-mrs.fr)



The therapeutic potential of bacteriocins as protein Antibiotics by
Hannah M. Behrens et al. 2017. Emerging Topics in Life Sciences
(2017) 1 65–74

Mode of action of LAB-bacteriocins

Gram-positive bacteria






Pore forming

μM CONCENTRATION


Cell – membrane target

nM CONCENTRATION





Docking molecules of LAB-Bacteriocins



COTTER et al. (2013). Nature Reviews Microbiology. 11: 95-105

RseP likely serves as the receptor for EntK1 and EntEJ97: stress response membrane-bound Zn dependent protease



Available online at www.sciencedirect.com

ScienceDirect

**Current Opinion in
Biotechnology**

Functions and emerging applications of bacteriocins

Michael L Chikindas^{1,2}, Richard Weeks¹, Djamel Drider³,
Vladimir A Chistyakov⁴ and Leon MT Dicks⁵



Probiotics & Antimicro. Prot.
DOI 10.1007/s12602-016-9223-0



Bacteriocins: Not Only Antibacterial Agents

Djamel Drider¹ · Farida Bendali² · Karim Naghmouchi³ · Michael L. Chikindas^{4,5}



Available online at www.sciencedirect.com

ScienceDirect

**Current Opinion in
Biotechnology**

Functions and emerging applications of bacteriocins

Michael L Chikindas^{1,2}, Richard Weeks¹, Djamel Drider³,
Vladimir A Chistyakov⁴ and Leon MT Dicks⁵



Probiotics & Antimicro. Prot.
DOI 10.1007/s12602-016-9223-0




Bacteriocins: Not Only Antibacterial Agents

Djamel Drider¹ · Farida Bendali² · Karim Naghmouchi³ · Michael L. Chikindas^{4,5}

LAB-BACTERIOCINS – Prof. D. Drider

Nisin (Nisaplin)
Nisin/colistin combination

Divercin V41
Class IIa
Carnobacterium divergens V41



Enterocin DD14
Leaderless class IIb
Enterococcus faecalis 14


E20 fraction
5 novel class II LAB-bacteriocins
Activity against *Escherichia coli* (*E. coli* mcr-1
EP 19178926.2)

Spectrum of Leaderless class II b Enterocin DD14


Listeria monocytogenes

↓
Clostridium perfringens

↓
Enterococcus faecalis V583 (VRE)

Methicillin Resistant
Staphylococcus aureus



Staphylococcus aureus




Anti-MRSA activity (MRSA-S1)

FICI values



Strains	DD14 ($\mu\text{g/mL}$)	Methicillin ($\mu\text{g/mL}$)	Met/DD14 ($\mu\text{g/mL}$)
<i>S. aureus</i> S1 (MRSA)	>200	4	0.5/30
<i>S. aureus</i> USA300 (MRSA)	>200	16	4/30
<i>S. aureus</i> ATCC 25923 (MSSA)	>200	0.5	0.25/30

Killing curves



Please remember MRSA-S1 is resistant to Erythromycin & DD14 + Erythromycin have a synergistic interaction

Development of nanobiotics anti-MRSA-S1




Alginate nanoparticles

EntDD14 + Alginate nanoparticles = **Nanobiotics**


- MIC Ent DD14 : 240 µg/ml
- MIC Ent DD14 + Alginate nanoparticles = 60 µg/ml
-

- (EntDD14 + Alginate Nanoparticles) + methicillin,
- MIC methicillin **4 à 0.25 µg/ml**

Anti-biofilm activity



Microbiological Research 252 (2021) 126364



Contents lists available at ScienceDirect

Microbiological Research

journal homepage: www.elsevier.com/locate/microres




SE


Potentiating effects of leaderless enterocin DD14 in combination with methicillin on clinical methicillin-resistant *Staphylococcus aureus* S1 strain

Yanath Belguesmia ^a, Giuseppe Spano ^b, Djamel Drider ^{a,*}

Biofilm: Cristal violet method
on polyester plates



Histological alterations following SARM infections, Erythromycin and/or DD14 treatments



Histological alterations following SARM infections, Erythromycin and/or DD14 treatments

A

Phylum



Beneficial Microbes, 2021 online

B

Genus >1%




ARTICLE IN PRESS

Cumulated relative population abundance (%)


Gut microbiota, body weight and histopathological examinations in experimental infection by methicillin-resistant *Staphylococcus aureus*: antibiotic versus bacteriocin

K. Bendjeddou¹, S. Hamma-Faradj¹, A. Ait Meddour¹, Y. Belguesmia², B. Cudennec², F. Bendali¹, G. Daube³, B. Taminiau³ and D. Drider^{2*}




Body weight evolution (statistic analysis)

A




Day 4
b *

E



Innovative strategy

Gut microbiota is an important source of bacteriocins and their expression can be explored for treatment of bacterial infections



Djamel DRIDER

Probiotics and Antimicrobial Proteins (Review in press)

DOI. 10.1007/s12602-021-09843-y

Financial supports and grants



FACTURE

**PHILEO
Lesaffre
International**

ANR
French Agency for
Research

La Région des
Hauts de France
Local authorities

Lille University



Agence Nationale de la Recherche
ANR





Colloque 16 Septembre 2021 (Paris)

Approches Innovantes dans la lutte contre l'antibiorésistance

Dr Philippe Gabant
Co-fondateur & CSO
pgabant@syngulon.com



TEAM / SAB / R&D Partners

Team



Guy Hélin, Co-founder, CEO
Dr. Philippe Gabant, Co-Founder, CSO



Dr. Mohamed El Bakkoury, CTO Yeast
Dr. Jason Bland, R&D Project Manager
Dr. Luz Perez, R&D Project Manager
Dr. Baptiste Dumont, R&D Project Manager
Félix Jaumaux, PhD Student
Dr. Anandi Martin, Senior Project Manager - Infectious Disease
Hajar Amraoui, PhD Student
Loïc Mues, R&D Scientist
Dr. Silvia Soto Diaz, R&D Project Manager



Collaboration with:
Universidad Complutense Madrid (UCM)
Dr. Juan Borrero



Scientific Advisory Board

Pr Joseph Martial (Chairman), ULg, Liège (BE)
Pr Bruno André, ULB, Brussels (BE)
Adj-Pr Mike Chandler, University of Georgetown (USA)



Pr Pascal Hols, UCL, Louvain-la-Neuve (BE)
Pr Didier Mazel, Institut Pasteur, Paris (FR)
Pr Laurence Van Melderen, ULB, Charleroi (BE)
Pr Ruddy Wattiez, UMons, Mons (BE)



IN MEMORIAM

Dr Régis Sodoyer, ex-Sanofi Pasteur, Lyon (FR)

R&D Partners



The importance of microbes for life on our planet





- Microbes are the chemical biocatalysers of our ecosystem
- Microbes are collaborating and fighting with each other to reach certain equilibrium to form communities: « microbiota »
- These microbiota have evolved to generate unique chemical reactions via species synergies





A Biobased Chemistry


- Improvements in energy storage
- An intensification of biotechnological processes



Bacteria and our health



Bacteriocin potential



- Production
- Genetic amenability
- Various prey spectrum
- Molecular diversity
- Cyto-friendly
- Stability
- Biological half-life

Pascal Hols, Laura Ledesma-García, Philippe Gabant and Johann Mignolet,
 Trends Microbiology 1685 No. of Pages 13



Bacteriocins as alternative to antibiotics




Broad spectrum antibiotics
VS
Narrow spectrum bacteriocins



Human microbiota is very variable



PRECISION MEDICINE



DATA




SORTED



ARRANGED




PRESENTED VISUALLY



EXPLAINED WITH A STORY




Evolution diversity of bacteriocins





PARAGEN 1.0: A Standardized Synthetic Gene Library for Fast Cell-Free Bacteriocin Synthesis


Philippe Gabant* and Juan Borrero†
Syngulon, Seraing, Belgium






To explore the diversity of bacteriocins we have built a collection of synthetic genes in a standardized format allowing rapid activity measurements of bacteriocins products.



Example of a potential application





Mutant Library generation to determine structure/function relationships



Cell-free Protein Synthesis*



Antimicrobial test



Type of mutations

- Alanine scan
- Deletion
- Single or multiple amino acid mutation
- (Charge variation)
- (Disulfides bound)



Félix Jaumaux



Prof Cédric Govaerts and Prof Abel Garcia-Pino


Professor
Pascal Hols




Screening of the PARAGEN collection




Félix Jaumaux



96 well plate containing chemically synthesized bacteriocins



Petri dish with a homogenous culture of a *Staphylococcus* strain



Observation of inhibition halos




Professor
Pascal Hols



Professor
Jacques Mahillon

Screening looking for bacteriocins active against *S. aureus* (7 strains tested)



Bacteriocins non active against *S. epidermidis* (2 strains tested)

A; B; C

Publications

BRIEF RESEARCH REPORT ARTICLE

Front. Bioeng. Biotechnol., 06 September 2019 | <https://doi.org/10.3389/fbioe.2019.00213>

PARAGEN 1.0: A Standardized Synthetic Gene Library for Fast Cell-Free Bacteriocin Synthesis

Philippe Gabant* and Juan Borrero†

Syngulon, Seraing, Belgium

[Home](#) / [Chimica Oggi-Chemistry Today](#) / [Vol. 38\(4\)](#) / Antimicrobial peptides to...

MICHAEL J. BLAND, PHILIPPE GABANT*

*Corresponding author

Syngulon, Seraing, Belgium

ANTIMICROBIAL PEPTIDES TO SHAPE BIOBASED CHEMICAL PRODUCTION

Keywords: anti-microbial peptides, antibiotics, bacteriocins, biotechnology, industrial fermentation, microbiome, one health

Other manuscripts in preparation

Subtle selectivity in a pheromone sensor triumvirate desynchronizes competence and predation in a human gut commensal

Johann Mignolet^{1,2*}, Guillaume Cerckel^{1†}, Julien Damoczi^{1†}, Laura Ledesma-Garcia¹, Andrea Sassi³, Tom Coenye³, Sylvie Nessler⁴, Pascal Hols¹

¹Biochemistry and Genetics of Microorganisms (BGM), Louvain Institute of Biomolecular Science and Technology, Université catholique de Louvain, Louvain-la-Neuve, Belgium; ²Syngulon, Seraing, Belgium; ³Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium; ⁴Institute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Univ. Paris-Sud, Université Paris-Saclay, 91198, Gif-sur-Yvette cedex, France



Trends in Microbiology

Review

Mobilization of Microbiota Commensals and Their Bacteriocins for Therapeutics

Pascal Hols,¹ Laura Ledesma-Garcia,¹ Philippe Gabant,² and Johann Mignolet ^{1,2,3,*}

Open Access Perspective

In the Age of Synthetic Biology, Will Antimicrobial Peptides be the Next Generation of Antibiotics?

by Félix Jaumaux , Luz P. Gómez de Cadiñanos  and Philippe Gabant * 

Syngulon, Rue du Bois Saint-Jean 15/1, 4102 Seraing, Belgium

* Author to whom correspondence should be addressed.

Antibiotics 2020, 9(8), 484; <https://doi.org/10.3390/antibiotics9080484>

Received: 14 July 2020 / Revised: 1 August 2020 / Accepted: 4 August 2020 / Published: 6 August 2020



Follow Us On



Take home message

1. Industries and the health sectors are looking for new ways to control microbial flora (microbiota)
2. Synthetic biology allows to apply biological functions at a new level
3. Bacteriocins are natural antimicrobial peptides (AMP) used by bacteria to protect their ecological niche
4. Syngulon has built PARAGEN a unique collection of synthetic bacteriocin genes (around 500 genes)
5. Via academic collaborations Syngulon is studying the mode of action of bacteriocins
6. Via different industrial/medical partnerships Syngulon is testing applications of bacteriocins

